Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

Labidi-Galy S. Intidhar; Rouge Thibault de La Motte; Derbel Olfa; Wolfer Anita; Kalbacher Elsa; Olivier Timothee; Combes Jean-Damien; Heimgartner-Hu Ketty; Tredan Olivier; Guevara Hemerson; Heudel Pierre-Etienne; Reverdy Thibaut; Bazan Fernando; Heinzelmann-Schwarz Viola; Fehr Mathias; de Castelbajac Victoire; Vaflard Pauline; Crivelli Louise; Bonadona Valerie; Viassolo Valeria; Buisson Adrien; Golmard Lisa; Rodrigues Manuel; Ray-Coquard Isabelle

首页> 外文期刊>Gynecologic Oncology: An International Journal >Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

【24h】

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

机译：奥拉帕里布延长反应和生存期相关的临床因素作为BRCA突变卵巢癌的维持治疗

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective: To investigate clinical factors associated with prolonged progression-free survival (PFS) and overall survival (OS) in relapsing epithelial ovarian cancer (EOC) patients with BRCA mutations and receiving olaparib as maintenance therapy in daily practice.

机译：目的：探讨与无延长的无进展生存（PFS）和整体存活（OS）相关的临床因素在倒塌上皮卵巢癌（EOC）BRCA突变患者中，并在日常实践中接受奥拉帕韦作为维持治疗。

著录项

来源
《Gynecologic Oncology: An International Journal》 |2019年第2期|共8页
作者
Labidi-Galy S. Intidhar; Rouge Thibault de La Motte; Derbel Olfa; Wolfer Anita; Kalbacher Elsa; Olivier Timothee; Combes Jean-Damien; Heimgartner-Hu Ketty; Tredan Olivier; Guevara Hemerson; Heudel Pierre-Etienne; Reverdy Thibaut; Bazan Fernando; Heinzelmann-Schwarz Viola; Fehr Mathias; de Castelbajac Victoire; Vaflard Pauline; Crivelli Louise; Bonadona Valerie; Viassolo Valeria; Buisson Adrien; Golmard Lisa; Rodrigues Manuel; Ray-Coquard Isabelle;
展开▼
作者单位

Hop Univ Geneve Dept Oncol Rue Gabrielle Perret Gentil 4 CH-1205 Geneva Switzerland;

Ctr Eugene Marquis Dept Med Oncol Rennes France;

Inst Canc Jean Mermoz Lyon France;

CHU Vaudois Dept Oncol Lausanne Switzerland;

CHU Besancon Div Med Oncol Besancon France;

Hop Univ Geneve Dept Oncol Rue Gabrielle Perret Gentil 4 CH-1205 Geneva Switzerland;

Int Agcy Res Canc Lyon France;

Hop Univ Geneve Dept Oncol Rue Gabrielle Perret Gentil 4 CH-1205 Geneva Switzerland;

Ctr Leon Berard Dept Med Oncol Lyon France;

Ctr Leon Berard Dept Med Oncol Lyon France;

Ctr Leon Berard Dept Med Oncol Lyon France;

Ctr Leon Berard Dept Med Oncol Lyon France;

CHU Besancon Div Med Oncol Besancon France;

Basel Univ Hosp Dept Gynecol Basel Switzerland;

Kantonsspital Frauenfeld Frauenklin Frauenfeld Switzerland;

PSL Res Univ Inst Curie Dept Med Oncol Paris France;

PSL Res Univ Inst Curie Dept Med Oncol Paris France;

Ctr Eugene Marquis Div Canc Genet Rennes France;

Ctr Leon Berard Unit Prevent &

Genet Epidemiol UMR CNRS 5558 Lyon France;

Hop Univ Geneve Dept Oncol Rue Gabrielle Perret Gentil 4 CH-1205 Geneva Switzerland;

Hosp Civiles Lyon Div Mol Genet Lyon France;

Inst Curie Div Genet Pole Med Diagnost &

Theranost Paris France;

PSL Res Univ Inst Curie Dept Med Oncol Paris France;

Ctr Leon Berard Dept Med Oncol Lyon France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
BRCA mutation; Olaparib; PARP inhibitor; Ovarian cancer; Maintenance; Survival; Prognostic;

机译：BRCA突变;Olaparib;PARP抑制剂;卵巢癌;维护;存活;预后;

相似文献

外文文献
中文文献
专利

1. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers [J] . Labidi-Galy S. Intidhar, Rouge Thibault de La Motte, Derbel Olfa, Gynecologic Oncology: An International Journal . 2019,第2期

机译：奥拉帕里布延长反应和生存期相关的临床因素作为BRCA突变卵巢癌的维持治疗
2. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome [J] . Cecere Sabrina Chiara, Giannone Gaia, Salutari Vanda, Gynecologic Oncology: An International Journal . 2020,第1期

机译：Olaparib作为BRCA患者的维持治疗1-2突变复发性铂敏感卵巢癌：现实世界数据和职业发布结果
3. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy [J] . Matulonis Ursula A., Harter Philipp, Gourley Charlie, Cancer: A Journal of the American Cancer Society . 2016,第12期

机译：铂敏感，复发性浆液性卵巢癌和BRCA突变的患者的Olaparib维持疗法：根据进展后的聚腺苷二磷酸核糖聚合酶抑制剂治疗调整总生存期
4. An Integrated Microfluidic Platform for Detecting BRCA1/BRCA2 Gene Mutation and Risk Assessment of Ovarian Cancer [C] . Yu-Hung Cheng, Chih-Hung Wang, Keng-Fu Hsu, International Conference on Solid-State Sensors, Actuators and Microsystems . 2021

机译：一种用于检测BRCA1 / BRCA2基因突变和卵巢癌风险评估的集成微流体平台
5. Nanomedicines and Combination Therapy of Doxorubicin and Olaparib for Treatment of Ovarian Cancer. [D] . Eetezadi, Sina. 2016

机译：阿霉素和奥拉帕比的纳米药物和联合疗法治疗卵巢癌。
6. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting [O] . Brian A. Dougherty, Zhongwu Lai, Darren R. Hodgson, 2017

机译：在维持环境中BRCA1和BRCA2体细胞突变作为olaparib反应的预测标志物的生物学和临床证据
7. PCN347 - EXPLORING THE IMPACT OF RADIOGRAPHIC PROGRESSIVE DISEASE AND FIRST SUBSEQUENT THERAPY ON HEALTH STATE UTILITY VALUES IN GERMLINE-BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC) PATIENTS ON OLAPARIB TABLETS AS MAINTENANCE MONOTHERAPY [O] . A. Sackeyfio, I. Santi, M. Friedlander 2018

机译：PCN347 - 探讨射线照相渐进疾病的影响，首次治疗奥帕里布蛋白敏感复发卵巢癌（PSROC）患者在奥拉帕里布片剂中作为维护单一疗法

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

摘要

著录项

相似文献

相关主题

期刊订阅